News
What you need to know about Moderna’s new COVID vaccine, just approved by the FDA
Moderna’s COVID shot had previously been approved for everyone 12 and older. The narrower approval follows the FDA announcing it was likely to limit access to immunizations among healthy children and adults under 65 this fall—as well as an announcement by Health Secretary Robert F.
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true ...
The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...
Trump HHS ends nearly $1 billion in funding to Moderna for mRNA bird flu vaccines, citing safety concerns and lack of ...
Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...
Zacks Investment Research on MSN2d
Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspikeModerna MRNA announced the FDA approval for mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, though for a ...
6don MSN
Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...
Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s ...
Health Secretary Robert F. Kennedy Jr. has repeatedly questioned the safety of mRNA technology, which is used in the ...
The Trump administration has canceled $766 million awarded to Moderna to develop a vaccine against potential pandemic ...
Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback